Loading clinical trials...

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice | Clinical Trials | Clareo Health

COMPLETED

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

NCT03425591•Janssen-Cilag Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy for chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Has a confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle-cell lymphoma (MCL), and is initiating ibrutinib therapy or has initiated ibrutinib therapy on or after 21 November 2014 (date of ibrutinib commercialization) for:
•1. treatment of CLL/SLL in participants who have received at least 1 prior therapy; or
•2. treatment in first line CLL/SLL participants in the presence of deletion (del) 17p or TP53 mutation in participants unsuitable for chemo-immunotherapy; or
•3. treatment of participants with relapsed or refractory MCL
•Not currently participating in another investigational study, clinical study, or any expanded access program at study entry
•Has not participated in the ibrutinib Autorisation Temporaire d'Utilisation (ATU) program
•Participant must sign a written informed consent form (ICF) allowing data collection and source data verification

Exclusion Criteria

•Currently participating in another investigational study, clinical study, or any expanded access program at study entry
•Participated in the ibrutinib Autorisation Temporaire d'Utilisation (ATU) program

Locations (1)

Paris, France

Key Dates

Start Date

May 11, 2016

Primary Completion Date

August 11, 2022

Completion Date

August 11, 2022

Last Updated

October 6, 2022

Enrollment

508

ACTUAL participants

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell

Interventions

Ibrutinib

DRUG

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

NCT07162181

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell+1 more

View study

ENROLLING_BY_INVITATION

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

NCT04911478

Lymphoma, FollicularLymphoma, Mantle-Cell+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

Inclusion Criteria

Exclusion Criteria

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion